AR053304A1 - Formas farmaceuticas orales protegidas frente al abuso con liberacion controlada de (1r,2r)-3-(3 dimetilamino-1-etil-2metil-propil)fenol y procedimiento para su produccion. - Google Patents
Formas farmaceuticas orales protegidas frente al abuso con liberacion controlada de (1r,2r)-3-(3 dimetilamino-1-etil-2metil-propil)fenol y procedimiento para su produccion.Info
- Publication number
- AR053304A1 AR053304A1 ARP050102719A ARP050102719A AR053304A1 AR 053304 A1 AR053304 A1 AR 053304A1 AR P050102719 A ARP050102719 A AR P050102719A AR P050102719 A ARP050102719 A AR P050102719A AR 053304 A1 AR053304 A1 AR 053304A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical form
- polymer
- wax
- phenol
- synthetic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Una forma farmacéutica oral, protegida frente al abuso, con liberacion controlada de (1R,2R)-3-(3-dimetilamino-1-etil-2-metil-propil)-fenol para una administracion unica diaria, caracterizada porque comprende el principio activo (A) y/o al menos uno varios de sus compuestos farmacéuticamente aceptables, al menos un polímero (C) sintético y/o natural, adyuvantes de liberacion sostenida, opcionalmente otros adyuvantes (B) fisiologicamente compatibles y opcionalmente una cera (D), de modo que el componente (C) o (D) presenta, cada uno, una resistencia a la rotura de al menos 500 N, preferiblemente de al menos 750 N. Reivindicacion 8: Forma farmacéutica segun una de las reivindicaciones 1 a 7, caracterizada porque el polímero (C) es a menos un polímero seleccionado del grupo que comprende poli(oxidos de etileno), polietilenos, polipropilenos, poli(cloruros de vinilo), policarbonatos, poliestirenos, poli(met)acrilatos, sus copolímeros y mezclas de al menos dos representantes de las clases poliméricas o polímeros mencionados. Reivindicacion 16. Forma farmacéutica segun una de las reivindicaciones 1 a 15, caracterizada porque como cera (D) está presente al menos una cera natural, semisintética y/o sintética con un punto de ablandamiento de al menos en 60°C. Reivindicacion 23: Forma farmacéutica segun una de las reivindicaciones 1 a 22, caracterizada porque presenta como adyuvante (B) al menos uno de los siguientes componentes (a9-(f) que impiden el abuso: a) al menos una sustancia que irrita la cavidad nasal y/o faríngea; b) al menos un agente que aumenta la viscosidad que, con ayuda de una cantidad mínima necesaria de un líquido acuoso, preferiblemente como un extracto acuoso obtenido a partir de la forma farmacéutica, forma un gel que preferiblemente al introducirlo en otra cantidad de un líquido acuoso puede seguir distinguiéndose visualmente; c) al menos un antagonista para el principio activo con potencial de crear dependencia; d) al menos un emético; e) al menos un colorante como agente de rechazo, f) al menos una sustancia amarga.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004032103A DE102004032103A1 (de) | 2004-07-01 | 2004-07-01 | Gegen Missbrauch gesicherte, orale Darreichungsform |
| US10/890,707 US20060039864A1 (en) | 2004-07-01 | 2004-07-14 | Abuse-proofed oral dosage form |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR053304A1 true AR053304A1 (es) | 2007-05-02 |
Family
ID=34972022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050102719A AR053304A1 (es) | 2004-07-01 | 2005-06-29 | Formas farmaceuticas orales protegidas frente al abuso con liberacion controlada de (1r,2r)-3-(3 dimetilamino-1-etil-2metil-propil)fenol y procedimiento para su produccion. |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1786403B1 (es) |
| JP (1) | JP5700904B2 (es) |
| KR (1) | KR101204657B1 (es) |
| AR (1) | AR053304A1 (es) |
| AU (1) | AU2005259478B2 (es) |
| BR (1) | BRPI0513300B1 (es) |
| CA (1) | CA2572352A1 (es) |
| NO (1) | NO337952B1 (es) |
| PL (1) | PL1786403T3 (es) |
| WO (1) | WO2006002886A1 (es) |
Cited By (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
| US8114383B2 (en) | 2003-08-06 | 2012-02-14 | Gruenenthal Gmbh | Abuse-proofed dosage form |
| US8114384B2 (en) | 2004-07-01 | 2012-02-14 | Gruenenthal Gmbh | Process for the production of an abuse-proofed solid dosage form |
| US8192722B2 (en) | 2003-08-06 | 2012-06-05 | Grunenthal Gmbh | Abuse-proof dosage form |
| US8383152B2 (en) | 2008-01-25 | 2013-02-26 | Gruenenthal Gmbh | Pharmaceutical dosage form |
| US8722086B2 (en) | 2007-03-07 | 2014-05-13 | Gruenenthal Gmbh | Dosage form with impeded abuse |
| US9161917B2 (en) | 2008-05-09 | 2015-10-20 | Grünenthal GmbH | Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet |
| US9636303B2 (en) | 2010-09-02 | 2017-05-02 | Gruenenthal Gmbh | Tamper resistant dosage form comprising an anionic polymer |
| US9655853B2 (en) | 2012-02-28 | 2017-05-23 | Grünenthal GmbH | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
| US9675610B2 (en) | 2002-06-17 | 2017-06-13 | Grünenthal GmbH | Abuse-proofed dosage form |
| US9737490B2 (en) | 2013-05-29 | 2017-08-22 | Grünenthal GmbH | Tamper resistant dosage form with bimodal release profile |
| US9855263B2 (en) | 2015-04-24 | 2018-01-02 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
| US9872835B2 (en) | 2014-05-26 | 2018-01-23 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
| US9913814B2 (en) | 2014-05-12 | 2018-03-13 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
| US9925146B2 (en) | 2009-07-22 | 2018-03-27 | Grünenthal GmbH | Oxidation-stabilized tamper-resistant dosage form |
| US10058548B2 (en) | 2003-08-06 | 2018-08-28 | Grünenthal GmbH | Abuse-proofed dosage form |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| US10080721B2 (en) | 2009-07-22 | 2018-09-25 | Gruenenthal Gmbh | Hot-melt extruded pharmaceutical dosage form |
| US10154966B2 (en) | 2013-05-29 | 2018-12-18 | Grünenthal GmbH | Tamper-resistant dosage form containing one or more particles |
| US10201502B2 (en) | 2011-07-29 | 2019-02-12 | Gruenenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
| US10300141B2 (en) | 2010-09-02 | 2019-05-28 | Grünenthal GmbH | Tamper resistant dosage form comprising inorganic salt |
| US10335373B2 (en) | 2012-04-18 | 2019-07-02 | Grunenthal Gmbh | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
| US10449547B2 (en) | 2013-11-26 | 2019-10-22 | Grünenthal GmbH | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
| US10624862B2 (en) | 2013-07-12 | 2020-04-21 | Grünenthal GmbH | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
| US10695297B2 (en) | 2011-07-29 | 2020-06-30 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
| US10729658B2 (en) | 2005-02-04 | 2020-08-04 | Grünenthal GmbH | Process for the production of an abuse-proofed dosage form |
| US10842750B2 (en) | 2015-09-10 | 2020-11-24 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
| US11224576B2 (en) | 2003-12-24 | 2022-01-18 | Grünenthal GmbH | Process for the production of an abuse-proofed dosage form |
| US11844865B2 (en) | 2004-07-01 | 2023-12-19 | Grünenthal GmbH | Abuse-proofed oral dosage form |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003024430A1 (en) | 2001-09-21 | 2003-03-27 | Egalet A/S | Morphine polymer release system |
| EP1429739A1 (en) | 2001-09-21 | 2004-06-23 | Egalet A/S | Polymer release system |
| US7906145B2 (en) | 2002-04-09 | 2011-03-15 | Flamel Technologies | Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s) |
| DE602004031096D1 (de) | 2003-03-26 | 2011-03-03 | Egalet As | Morphin-system mit kontrollierter freisetzung |
| FR2901478B1 (fr) * | 2006-05-24 | 2015-06-05 | Flamel Tech Sa | Forme pharmaceutique orale multimicroparticulaire a liberation prolongee |
| US9023400B2 (en) | 2006-05-24 | 2015-05-05 | Flamel Technologies | Prolonged-release multimicroparticulate oral pharmaceutical form |
| SA07280459B1 (ar) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
| US8821928B2 (en) | 2007-06-04 | 2014-09-02 | Egalet Ltd. | Controlled release pharmaceutical compositions for prolonged effect |
| US9005660B2 (en) | 2009-02-06 | 2015-04-14 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
| CA2766179A1 (en) | 2009-06-24 | 2010-12-29 | Egalet Ltd. | Controlled release formulations |
| US8397733B2 (en) * | 2010-01-15 | 2013-03-19 | Celanese Acetate Llc | Degradable cigarette filter: pill with multilayered coating |
| WO2011095314A2 (en) | 2010-02-03 | 2011-08-11 | Grünenthal GmbH | Preparation of a powdery pharmaceutical composition by means of an extruder |
| CA2832436C (en) * | 2010-04-07 | 2018-08-14 | Lupin Limited | Controlled release pharmaceutical compositions of tapentadol |
| DK3650439T3 (da) | 2010-07-23 | 2021-03-08 | Gruenenthal Gmbh | Salte eller co-krystaller af 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol |
| EP2611428B1 (en) | 2010-09-02 | 2015-01-14 | Grünenthal GmbH | Tamper resistant dosage form comprising an anionic polymer |
| WO2012119728A1 (en) | 2011-03-04 | 2012-09-13 | Grünenthal GmbH | Parenteral administration of tapentadol |
| WO2012119729A1 (en) | 2011-03-04 | 2012-09-13 | Grünenthal GmbH | Semisolid aqueous pharmaceutical composition containing tapentadol |
| PT2680832T (pt) | 2011-03-04 | 2019-10-28 | Gruenenthal Gmbh | Formulação farmacêutica aquosa de tapentadol para administração oral |
| BR112014008120A2 (pt) | 2011-10-06 | 2017-04-11 | Gruenenthal Gmbh | forma inviolável de dosagem farmacêutica oral compreendendo agonista de opioide e antagonista de opioide |
| KR20140096062A (ko) | 2011-11-17 | 2014-08-04 | 그뤼넨탈 게엠베하 | 약리학적 활성 성분, 오피오이드 길항제 및/또는 혐오제, 폴리알킬렌 옥사이드 및 음이온성 중합체를 포함하는 탬퍼-저항성 경구 약제학적 투여형 |
| WO2013127830A1 (en) | 2012-02-28 | 2013-09-06 | Grünenthal GmbH | Tamper-resistant pharmaceutical dosage form comprising nonionic surfactant |
| CA2870012A1 (en) | 2012-05-11 | 2013-11-14 | Grunenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| JP2015521988A (ja) | 2012-07-06 | 2015-08-03 | イガレット・リミテッド | 制御放出用乱用防止性医薬組成物 |
| WO2014106865A1 (en) * | 2013-01-07 | 2014-07-10 | Alkem Laboratories Ltd. | Abuse-proofed, extended release pharmaceutical composition comprising tapentadol or a pharmaceutically acceptable salt thereof and processes for preparing thereof |
| EP2808319A1 (en) | 2013-05-31 | 2014-12-03 | Arevipharma GmbH | 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex |
| WO2015071248A1 (en) | 2013-11-15 | 2015-05-21 | Synthon B.V. | Abuse-proofed extended release pharmaceutical composition comprising tapentadol |
| CA2933983A1 (en) | 2013-12-16 | 2015-06-25 | Grunenthal Gmbh | Tamper resistant dosage form with bimodal release profile manufactured by co-extrusion |
| CA2975653A1 (en) | 2015-02-03 | 2016-08-11 | Grunenthal Gmbh | Tamper-resistant dosage form comprising a polyethylene glycol graft copolymer |
| HUE042612T2 (hu) | 2015-03-27 | 2019-07-29 | Gruenenthal Gmbh | Parenterális alkalmazású stabil Tapentadol készítmény |
| EP3285748A1 (en) | 2015-04-24 | 2018-02-28 | Grünenthal GmbH | Tamper-resistant fixed dose combination providing fast release of two drugs from different particles |
| AU2016251302A1 (en) | 2015-04-24 | 2017-11-23 | Grünenthal GmbH | Tamper-resistant fixed dose combination providing fast release of two drugs from particles and a matrix |
| CA2983634A1 (en) | 2015-04-24 | 2016-10-27 | Grunenthal Gmbh | Tamper-resistant fixed dose combination providing fast release of two drugs from particles |
| WO2017085734A1 (en) | 2015-11-17 | 2017-05-26 | Msn Laboratories Private Limited | Crystalline forms of tapentadol salts and process for preparation thereof |
| KR20170003380U (ko) | 2016-03-21 | 2017-09-29 | 정화정 | 공기주입식 간판의 받침장치 |
| US20170296476A1 (en) | 2016-04-15 | 2017-10-19 | Grünenthal GmbH | Modified release abuse deterrent dosage forms |
| CA3029869A1 (en) | 2016-07-06 | 2018-01-11 | Grunenthal Gmbh | Reinforced pharmaceutical dosage form |
| EP3490537A1 (en) | 2016-08-01 | 2019-06-05 | Grünenthal GmbH | Tamper resistant dosage form comprising an anionic polysaccharide |
| CA3033423A1 (en) | 2016-08-12 | 2018-02-15 | Grunenthal Gmbh | Tamper resistant formulation of ephedrine and its derivatives |
| JP7160799B2 (ja) | 2016-09-23 | 2022-10-25 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | タペンタドールの非経口投与用安定製剤 |
| EP3585370A1 (en) | 2017-02-23 | 2020-01-01 | Grünenthal GmbH | Tapentadol as local anesthetic |
| US20190110992A1 (en) | 2017-10-13 | 2019-04-18 | Grünenthal GmbH | Modified release abuse deterrent dosage forms |
| TW202002957A (zh) | 2018-02-09 | 2020-01-16 | 德商歌林達有限公司 | 包含轉化抑制劑之麻黃素及其衍生物之抗損壞調配物 |
| EP3698776A1 (en) | 2019-02-19 | 2020-08-26 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
| EP3875077B1 (en) * | 2020-03-02 | 2023-12-13 | Grünenthal GmbH | Dosage form providing prolonged release of tapentadol phosphoric acid salt |
| EP3875079A1 (en) | 2020-03-02 | 2021-09-08 | Grünenthal GmbH | Dosage form providing prolonged release of tapentadol phosphoric acid salt |
| AU2020100441B4 (en) * | 2020-03-02 | 2020-06-18 | Grünenthal GmbH | Dosage form providing prolonged release of tapentadol phosphoric acid salt |
| EP4003318A1 (en) | 2020-03-02 | 2022-06-01 | Grünenthal GmbH | Dosage form providing prolonged release of tapentadol phosphoric acid salt |
| AU2020100442B4 (en) * | 2020-03-02 | 2020-06-18 | Grünenthal GmbH | Dosage form providing prolonged release of tapentadol phosphoric acid salt |
| WO2021219576A1 (en) | 2020-04-27 | 2021-11-04 | Grünenthal GmbH | Multiparticulate dosage form containing eva copolymer and additional excipient |
| WO2021219577A1 (en) | 2020-04-27 | 2021-11-04 | Grünenthal GmbH | Dosage form comprising hot-melt extruded pellets containing eva copolymer and gliding agent |
| DE202020104285U1 (de) | 2020-07-24 | 2020-12-18 | Grünenthal GmbH | Ethylcellulose-beschichtete Partikel enthaltend ein Salz aus Tapentadol und Phosphorsäure |
| WO2022101247A1 (de) | 2020-11-10 | 2022-05-19 | Grünenthal GmbH | Darreichungsformen mit verlängerter freisetzung eines salzes von tapentadol mit l-(+)-weinsäure |
| DE202020005470U1 (de) | 2020-11-10 | 2022-01-25 | Grünenthal GmbH | Darreichungsformen mit verlängerter Freisetzung eines Salzes von Tapentadol mit L-(+)-Weinsäure |
| HUE059465T2 (hu) | 2020-11-10 | 2022-11-28 | Gruenenthal Gmbh | A tapentadol L-(+)- borkõsav-só késleltetett felszabadulású adagolási formája |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5004601A (en) * | 1988-10-14 | 1991-04-02 | Zetachron, Inc. | Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith |
| ATE211906T1 (de) * | 1996-03-12 | 2002-02-15 | Alza Corp | Zusammensetzung und dosisform mit einem opioid- antagonisten |
| US7332182B2 (en) * | 2001-08-06 | 2008-02-19 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant |
| US7144587B2 (en) * | 2001-08-06 | 2006-12-05 | Euro-Celtique S.A. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent |
| PE20030527A1 (es) * | 2001-10-24 | 2003-07-26 | Gruenenthal Chemie | Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen |
| DE10250083A1 (de) * | 2002-06-17 | 2003-12-24 | Gruenenthal Gmbh | Gegen Missbrauch gesicherte Darreichungsform |
| US7399488B2 (en) * | 2002-07-05 | 2008-07-15 | Collegium Pharmaceutical, Inc. | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
| DE10250087A1 (de) * | 2002-10-25 | 2004-05-06 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| DE10250088A1 (de) * | 2002-10-25 | 2004-05-06 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| DE10250084A1 (de) * | 2002-10-25 | 2004-05-06 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
-
2005
- 2005-06-29 EP EP05758495.5A patent/EP1786403B1/de active Active
- 2005-06-29 PL PL05758495T patent/PL1786403T3/pl unknown
- 2005-06-29 WO PCT/EP2005/006990 patent/WO2006002886A1/de active Application Filing
- 2005-06-29 CA CA002572352A patent/CA2572352A1/en not_active Abandoned
- 2005-06-29 AU AU2005259478A patent/AU2005259478B2/en not_active Ceased
- 2005-06-29 JP JP2007518529A patent/JP5700904B2/ja not_active Expired - Fee Related
- 2005-06-29 BR BRPI0513300A patent/BRPI0513300B1/pt not_active IP Right Cessation
- 2005-06-29 KR KR1020077000734A patent/KR101204657B1/ko active Protection Beyond IP Right Term
- 2005-06-29 AR ARP050102719A patent/AR053304A1/es not_active Application Discontinuation
-
2007
- 2007-01-31 NO NO20070578A patent/NO337952B1/no not_active IP Right Cessation
Cited By (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9675610B2 (en) | 2002-06-17 | 2017-06-13 | Grünenthal GmbH | Abuse-proofed dosage form |
| US10369109B2 (en) | 2002-06-17 | 2019-08-06 | Grünenthal GmbH | Abuse-proofed dosage form |
| US8114383B2 (en) | 2003-08-06 | 2012-02-14 | Gruenenthal Gmbh | Abuse-proofed dosage form |
| US8192722B2 (en) | 2003-08-06 | 2012-06-05 | Grunenthal Gmbh | Abuse-proof dosage form |
| US8309060B2 (en) | 2003-08-06 | 2012-11-13 | Grunenthal Gmbh | Abuse-proofed dosage form |
| US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
| US10130591B2 (en) | 2003-08-06 | 2018-11-20 | Grünenthal GmbH | Abuse-proofed dosage form |
| US8420056B2 (en) | 2003-08-06 | 2013-04-16 | Grunenthal Gmbh | Abuse-proofed dosage form |
| US10058548B2 (en) | 2003-08-06 | 2018-08-28 | Grünenthal GmbH | Abuse-proofed dosage form |
| US9629807B2 (en) | 2003-08-06 | 2017-04-25 | Grünenthal GmbH | Abuse-proofed dosage form |
| US11224576B2 (en) | 2003-12-24 | 2022-01-18 | Grünenthal GmbH | Process for the production of an abuse-proofed dosage form |
| US11844865B2 (en) | 2004-07-01 | 2023-12-19 | Grünenthal GmbH | Abuse-proofed oral dosage form |
| US8114384B2 (en) | 2004-07-01 | 2012-02-14 | Gruenenthal Gmbh | Process for the production of an abuse-proofed solid dosage form |
| US8323889B2 (en) | 2004-07-01 | 2012-12-04 | Gruenenthal Gmbh | Process for the production of an abuse-proofed solid dosage form |
| US10729658B2 (en) | 2005-02-04 | 2020-08-04 | Grünenthal GmbH | Process for the production of an abuse-proofed dosage form |
| US10675278B2 (en) | 2005-02-04 | 2020-06-09 | Grünenthal GmbH | Crush resistant delayed-release dosage forms |
| US8722086B2 (en) | 2007-03-07 | 2014-05-13 | Gruenenthal Gmbh | Dosage form with impeded abuse |
| US8383152B2 (en) | 2008-01-25 | 2013-02-26 | Gruenenthal Gmbh | Pharmaceutical dosage form |
| US9750701B2 (en) | 2008-01-25 | 2017-09-05 | Grünenthal GmbH | Pharmaceutical dosage form |
| US9161917B2 (en) | 2008-05-09 | 2015-10-20 | Grünenthal GmbH | Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet |
| US9925146B2 (en) | 2009-07-22 | 2018-03-27 | Grünenthal GmbH | Oxidation-stabilized tamper-resistant dosage form |
| US10080721B2 (en) | 2009-07-22 | 2018-09-25 | Gruenenthal Gmbh | Hot-melt extruded pharmaceutical dosage form |
| US10493033B2 (en) | 2009-07-22 | 2019-12-03 | Grünenthal GmbH | Oxidation-stabilized tamper-resistant dosage form |
| US10300141B2 (en) | 2010-09-02 | 2019-05-28 | Grünenthal GmbH | Tamper resistant dosage form comprising inorganic salt |
| US9636303B2 (en) | 2010-09-02 | 2017-05-02 | Gruenenthal Gmbh | Tamper resistant dosage form comprising an anionic polymer |
| US10864164B2 (en) | 2011-07-29 | 2020-12-15 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
| US10695297B2 (en) | 2011-07-29 | 2020-06-30 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
| US10201502B2 (en) | 2011-07-29 | 2019-02-12 | Gruenenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
| US9655853B2 (en) | 2012-02-28 | 2017-05-23 | Grünenthal GmbH | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
| US10335373B2 (en) | 2012-04-18 | 2019-07-02 | Grunenthal Gmbh | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| US10154966B2 (en) | 2013-05-29 | 2018-12-18 | Grünenthal GmbH | Tamper-resistant dosage form containing one or more particles |
| US9737490B2 (en) | 2013-05-29 | 2017-08-22 | Grünenthal GmbH | Tamper resistant dosage form with bimodal release profile |
| US10624862B2 (en) | 2013-07-12 | 2020-04-21 | Grünenthal GmbH | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
| US10449547B2 (en) | 2013-11-26 | 2019-10-22 | Grünenthal GmbH | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
| US9913814B2 (en) | 2014-05-12 | 2018-03-13 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
| US9872835B2 (en) | 2014-05-26 | 2018-01-23 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
| US9855263B2 (en) | 2015-04-24 | 2018-01-02 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
| US10842750B2 (en) | 2015-09-10 | 2020-11-24 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
Also Published As
| Publication number | Publication date |
|---|---|
| NO337952B1 (no) | 2016-07-18 |
| CA2572352A1 (en) | 2006-01-12 |
| EP1786403A1 (de) | 2007-05-23 |
| JP5700904B2 (ja) | 2015-04-15 |
| JP2008504328A (ja) | 2008-02-14 |
| AU2005259478B2 (en) | 2010-07-15 |
| PL1786403T3 (pl) | 2013-10-31 |
| KR20070039041A (ko) | 2007-04-11 |
| EP1786403B1 (de) | 2013-07-24 |
| KR101204657B1 (ko) | 2012-11-27 |
| NO20070578L (no) | 2007-01-31 |
| AU2005259478A1 (en) | 2006-01-12 |
| BRPI0513300B1 (pt) | 2018-11-06 |
| BRPI0513300A (pt) | 2008-05-06 |
| WO2006002886A1 (de) | 2006-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR053304A1 (es) | Formas farmaceuticas orales protegidas frente al abuso con liberacion controlada de (1r,2r)-3-(3 dimetilamino-1-etil-2metil-propil)fenol y procedimiento para su produccion. | |
| AR049562A1 (es) | Formas farmaceuticas orales, con liberacion controlada de opioides, protegidas frente al abuso y procedimiento para su preparacion | |
| PE20061087A1 (es) | Formas farmaceuticas resistente a la rotura con liberacion sostenida | |
| AR049979A1 (es) | Composicion oftalmica util para la colocacion intraocular en un ojo de un ser humano o animal y uso de un componente corticosteroide, un componente polimerico biocompatible y un componente solvente oftalmicamente compatible en una cantidad efectiva para solubilizar el componente polimerico para prep | |
| AR038575A1 (es) | Formulacion oftalmica con nueva composicion de goma | |
| HK1110774A1 (en) | Oral dosage form safeguarded against abuse containing (1r,2r)-3-(3- dimethylamino-1-ethyl-2-methyl-propyl)-phenol | |
| PE20060523A1 (es) | Formas farmaceuticas orales de opioides con liberacion controlada | |
| WO2004112748A3 (en) | Rate controlled release of a pharmaceutical agent in a biodegradable device | |
| AR073460A1 (es) | Dispositivo oftalmico con capacidad de administracion de agente terapeutico y metodo de formacion del mismo | |
| DE60231862D1 (de) | Erodierbare polymere zur injektion | |
| BRPI0413381A (pt) | composições para liberação de compostos terapêuticos nos olhos e processos para fabricação e uso das mesmas | |
| AR045352A1 (es) | Forma de dosificacion a prueba de abuso | |
| WO2005099667A3 (en) | Drug delivery compositions | |
| AR034324A1 (es) | Composicion farmaceutica que posee caracteristicas farmacocineticas incrementadas | |
| BR0212475A (pt) | Composições farmacêuticas | |
| WO2010068281A3 (en) | Contact lens drug delivery device | |
| AR048033A1 (es) | Composicion farmaceutica para moldear componentes que comprende copolimero de poli(met)acrilato, cubierta, conector o espaciador de capsula moldeado por inyeccion que tiene la composicion farmaceutica y forma de dosificacion farmaceutica de multicomponentes a partir de dicha composicion | |
| BRPI0506983A (pt) | composições para terapia localizada dos olhos, compreendendo preferencialmente acetonida de triancinolona e ácido hialurÈnico | |
| CR9864A (es) | Formas de presentacion farmaceutica solidas de administracion oral con liberacion rapida de principio activo | |
| CL2003002277A1 (es) | Composicion farmaceutica inyectable, de deposito de liberacion prolongada, que comprende un agente beneficioso disuelto o disperso en un gel constituido por un polimero bioerosionable y biocompatible; y un solvente. | |
| CY1109606T1 (el) | Βιοδιασπωμενο υμενιο για την απελευθερωση φαρμακου στον οφθαλμο | |
| CN102448411A (zh) | 泪点塞 | |
| ES2421916T3 (es) | Forma farmacéutica de sabor enmascarado que contiene roflumilast | |
| KR20120013346A (ko) | 누점 마개 | |
| US20190117850A1 (en) | Microneedle Structure For Efficient Skin Perforation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |